AstraZeneca (LSE:AZN) Puts AI Into Biologics Labs With New Discovery Tie Up

What happened: AstraZeneca (LSE:AZN) announced an AI-driven biologics discovery collaboration with Carterra ahead of trading on 9 October 2026, linking its AI models to Carterra biosensor instruments for lab-in-the-loop workflows. Key numbers: Market cap £186.1 billion. Fair value cited at £159. Why it matters: The tie-up tests the view that AI spending can speed drug development and support margins. Analysts question whether it offsets patent expiries, price controls and heavy R&D, with Pfizer and Merck also using AI. Market: -0.5% by next close ($158.33 on Oct 12), -10.6% YTD

AstraZeneca (LSE:AZN) announced an AI-driven biologics discovery collaboration with Carterra ahead of trading on 9 October 2026, linking its AI models to Carterra biosensor instruments for lab-in-the-loop workflows.

The tie-up tests the view that AI spending can speed drug development and support margins. Analysts question whether it offsets patent expiries, price controls and heavy R&D, with Pfizer and Merck also using AI. Market: -0.5% by next close ($158.33 on Oct 12), -10.6% YTD